Page last updated: 2024-12-11

ethyl linolenate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ethyl linolenate : A long-chain fatty acid ethyl ester resulting from the formal condensation of the carboxy group of linolenic acid with the hydroxy group of ethanol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6371716
CHEMBL ID1527567
SCHEMBL ID4814472
MeSH IDM0119121

Synonyms (17)

Synonym
9,12,15-octadecatrienoic acid ethyl ester
ethyl-9,12,15-octadecatrienoate
nsc607760
ethyl linolenate
NCGC00091069-01
ethyl octadeca-9,12,15-trienoate
NCGC00091069-02
NCGC00091069-03
AKOS015894287
SCHEMBL4814472
CHEMBL1527567
cis-9,cis-12,cis-15 octadecadienoic acid ethyl ester
(9e,12e,15e)-ethyl octadeca-9,12,15-trienoate
trans,trans,trans-octadeca-9,12,15-trienoic acid ethyl ester
alaee
ethyl linolenoate; ethyl -linolenate
ethyl linilenate

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" 2"-O-GIV exhibited a dose-response effect but alpha-tocopherol did not."( Inhibitory effect of 2"-O-glycosyl isovitexin and alpha-tocopherol on genotoxic glyoxal formation in a lipid peroxidation system.
Hagiwara, H; Hagiwara, Y; Nishiyama, T; Shibamoto, T, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency15.84890.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
15-lipoxygenase, partialHomo sapiens (human)Potency2.51190.012610.691788.5700AID887
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency1.12200.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.06310.001318.074339.8107AID926; AID938
retinoid X nuclear receptor alphaHomo sapiens (human)Potency42.23950.000817.505159.3239AID588544; AID588546
farnesoid X nuclear receptorHomo sapiens (human)Potency63.09570.375827.485161.6524AID588526
pregnane X nuclear receptorHomo sapiens (human)Potency14.12540.005428.02631,258.9301AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency50.11870.000229.305416,493.5996AID588513
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency47.39350.001024.504861.6448AID588534; AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency44.66840.001019.414170.9645AID588537
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency44.66840.023723.228263.5986AID588543
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency28.18380.01789.637444.6684AID588834
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency63.19070.000627.21521,122.0200AID651741; AID720636
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (31.25)18.7374
1990's2 (12.50)18.2507
2000's6 (37.50)29.6817
2010's2 (12.50)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]